Original article PDF Hyunjung Kim1, Hyun Yong Jeong2,3,4, Sangkwon Han1, Shinhun Han1, Jungil Choi1, Bonghwan Jin1, Taegeun Lim1,2,3, Eun-Geun Kim1, Dong Young Kim1, Sang Hoon Song5, Taek Soo Kim5, Sunghoon Kwon1,2,3,4,6 1QuantaMatrix Inc., 2Institutes of Entrepreneurial BioConvergence, Seoul National University, 3Department of Electrical and Computer Engineering, Seoul National University, 4Department of Transdisciplinary Studies, Seoul National University, 5Department of Laboratory Medicine, Seoul National University Hospital, 6Seoul National University Hospital Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea Corresponding to Sunghoon Kwon, E-mail: skwon@snu.ac.kr Ann Clin Microbiol 2018;21(1):12-19. https://doi.org/10.5145/ACM.2018.21.1.12Copyright © Korean Society of Clinical Microbiology. Abstract Background: Timely intervention in the treatment of bloodstream infection is important for prescription of appropriate antimicrobials. With prompt determination of the antimicrobial susceptibility of a causative agent, rapid antimicrobial susceptibility test (AST) can help select the appropriate antimicrobial therapy. This clinical study is for evaluation of the clinical performance of the QMAC-dRAST for rapid AST directly from positive blood culture